glp 1 drugs for weight loss reviews GLP-1 Medications Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness adverse effects of glp-1 receptor
Description
Continue covering weight loss drugs and raise premiums for everyone, or restrict coverage and protect the broader member pool from unsustainable cost increases
It is not recommended in pregnancy or breastfeeding without provider direction
Tirzepatide studies showed only 2.4% of participants developed type 2 diabetes, compared to 13.7% taking placebo 7
Dedicated histological reassessment studies after GLP-1 RA discontinuation in MASH patients are currently lacking, representing a major evidence gap
E.et al (2021)
